Financial Performance - For the nine months ended September 30, 2025, the company reported a net loss of $81.6 million, compared to a net loss of $56.4 million for the same period in 2024, resulting in an accumulated deficit of $281.0 million as of September 30, 2025[105]. - The net loss attributable to common stockholders for the three months ended September 30, 2025, was $29.4 million, compared to a net loss of $19.0 million in 2024, reflecting an increase of $10.4 million[130]. - For the nine months ended September 30, 2025, total operating expenses were $85.7 million, compared to $60.2 million in 2024, an increase of $25.5 million[135]. - Total operating expenses for the three months ended September 30, 2025, increased to $31.5 million from $20.9 million in the same period of 2024, representing a change of $10.6 million[130]. - Interest income for the nine months ended September 30, 2025, was $3.0 million, down from $3.6 million in 2024, a decrease of $0.6 million due to reduced investments[139]. - Cash flows used in operating activities for the nine months ended September 30, 2025, were $91.3 million, compared to $57.3 million in 2024, reflecting an increase of $33.9 million[144]. Revenue Generation - The company has not generated any revenue from product sales to date and does not expect to do so in the foreseeable future[114]. - The company expects to finance operations through public or private equity offerings and debt financings until substantial revenue is generated from product sales[154]. Research and Development - The company expects to incur significant and increasing expenses and net losses as it advances its product candidates through clinical development and seeks regulatory approval[105]. - The company anticipates that research and development expenses will continue to increase substantially as it conducts clinical trials and develops additional product candidates[117]. - The lead product candidate, ML-007C-MA, is currently undergoing two Phase 2 trials, with topline results expected in the second half of 2026 and 2027 for schizophrenia and Alzheimer's disease psychosis, respectively[103]. - The company plans to increase research and development expenses as it continues clinical trial activities and advances preclinical programs, but cannot estimate future costs or timelines for product development[150]. - The company has incurred significant costs related to research and development, including salaries, external development activities, and clinical trial expenses, but cannot accurately predict future costs or timelines for product development[118]. Cash and Investments - As of September 30, 2025, the company had cash, cash equivalents, and short-term investments totaling $227.2 million, with an expectation that the estimated net proceeds from the IPO and concurrent private placement will fund operations through 2027[109]. - The company closed its IPO in October 2025, issuing 16,962,500 shares at a price of $17.00 per share, resulting in gross proceeds of $288.4 million and estimated net proceeds of approximately $262.3 million[143]. - Net cash provided by financing activities increased to $197.9 million for the nine months ended September 30, 2025, compared to $118.1 million for the same period in 2024, mainly due to proceeds from the issuance of Series D Preferred Stock[149]. - Net cash used in investing activities decreased to $80.7 million for the nine months ended September 30, 2025, from $113.2 million in the same period of 2024, primarily due to the maturities of short-term investments[148]. Expenses - General and administrative expenses are expected to rise as the company increases personnel to support clinical development and incurs costs associated with being a public company[123]. - General and administrative expenses for the nine months ended September 30, 2025, were $12.0 million, a decrease from $12.4 million in 2024, primarily due to a reduction in professional fees[138]. - Research and development expenses for the three months ended September 30, 2025, were $27.1 million, up from $16.8 million in 2024, an increase of $10.3 million primarily due to an $8.0 million rise in clinical trial expenses[131]. Future Obligations and Risks - The company is subject to potential future payments under grant agreements and licensing agreements contingent upon achieving regulatory and commercial milestones, but cannot estimate the timing or likelihood of these milestones[158][159]. - The company has contractual obligations for lease agreements totaling $7.0 million from January 1, 2025, through the end of the lease term in June 2031[155]. - The company has no outstanding debt as of September 30, 2025, which eliminates interest rate risk related to debt[169]. Economic Factors - Inflation has not had a material effect on the company's consolidated financial statements, although it generally increases labor and clinical trial costs[172]. - The company does not currently engage in currency hedging activities but may consider it in the future to manage foreign currency exposure[171].
MapLight Therapeutics(MPLT) - 2025 Q3 - Quarterly Report